You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

riTUXimab

( rit-TUCKS-ee-mab )
Funding:
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
  • Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
  • Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
... Show more tags
Other Name(s): Rituxan®; Truxima™; Riximyo™; Ruxience™
Appearance: Clear, colourless solution mixed into larger bags of fluids

Drug Monograph

Aug 2020
Table of Contents
Eligibility Forms
pdf download Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL pdf download Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia pdf download Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia pdf download Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia pdf download Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia pdf download Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma pdf download Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Patient Info Sheet

Oct 2020

What it is used for

  • For treating blood cancers such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)
     
  • Rituximab is available as a biosimilar medication. See our biosimilar pamphlet for more information. 


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration